China courier puts sick daughter in delivery box while working as she can't afford childcare
The woman, surnamed Zhu, and her child were caught on camera by an online influencer in eastern China's Anhui province.
The 25-year-old delivered food on an electric bicycle in the summer heat while carrying her daughter in the box attached to the vehicle.
The girl has a vein-detained needle on one hand and a chemo port on her chest.
Zhu feeds her four-year-old daughter between deliveries as she sits in the courier box. Photo: Douyin
Her mother, surnamed Zhu, said the girl, Nuoxi, was diagnosed with a tumour two years ago.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
8 minutes ago
- South China Morning Post
China reports 7,000 cases of mosquito-borne chikungunya virus
More than 7,000 cases of a mosquito-borne virus have been reported across China's southern Guangdong province since July 2025. Hong Kong has also reported several imported cases of the virus.
South China Morning Post
6 hours ago
- South China Morning Post
‘Dormant bombs': unique genes that make us smart may also fuel cancer, China study shows
A genetic study in China that could have major implications for human evolution – and cancer research – has shown that a special type of recently evolved gene can be sequestered by cancerous tumours to fuel their growth. The team of researchers from Peking University and the Chinese Academy of Sciences (CAS) examined a group of young genes that emerged de novo, meaning they recently evolved from regions of the genome that do not code for proteins rather than from coding genes through typical gene evolution Unlike most genes, which evolve from existing genes through duplication and modification, 'motherless' de novo genes come from DNA that previously had no function. These new genes are thought to be key to some uniquely human traits, such as our advanced cognitive abilities and susceptibility to certain diseases. 'We identified 37 young de novo genes,' the team said in a paper published in the peer-reviewed journal Cell Genomics on July 17, adding that they found strong evidence that these genes were functional and actively coded for the creation of proteins. 'Collectively, this set of 37 genes represents the most rigorously validated catalogue of young human de novo genes to date.' The researchers said that the expression of these genes was 'significantly' increased in tumours, while the deletion of some of the genes could suppress the proliferation of tumour cells.
South China Morning Post
9 hours ago
- South China Morning Post
Sunshine Lake Pharma falls in Hong Kong trading debut as market's IPO buzz takes a breath
Sunshine Lake Pharma's shares fell in their trading debut in Hong Kong, as the city's buzz over first-day trading took a breather while the stock market sought fresh directions from mainland China's macroeconomic statistics and trade talks. Advertisement Trading under the stock sign 6887, Sunshine's shares began trading at HK$57.50 on Thursday, a discount of 4.5 per cent to its initial public offer price of HK$60.24 in Hong Kong. Known also as Guangdong Dongyangguang Pharmaceutical, Sunshine is one of more than 50 drug companies that are looking to raise capital in Hong Kong, answering a drive by the bourse operator Hong Kong Exchanges and Clearing (HKEX), which has turned the city into the world's second-largest fundraising hub for pharmaceutical and medical research start-ups. 'The company will accelerate the integration of high-quality resources, speed up the commercialisation and globalisation of its innovative drug pipeline, and inject strong momentum into sustainable growth', Sunshine's chairman Zhang Yingjun said at the HKEX's Connect Hall, before striking a ceremonial gong to mark the commencement of trading. 'Our responsibility is heavy and the road is long, but we will dedicate ourselves to our chosen path. This listing is a new starting point for us. We will follow the path of hi-tech R&D and innovation to produce excellent medicines for patients and improve our performance to build a world-class pharmaceutical company.' Advertisement
